scholarly journals Lubiprostone Decreases the Small Bowel Transit Time by Capsule Endoscopy: An Exploratory, Randomised, Double-Blind, Placebo-Controlled 3-Way Crossover Study

2014 ◽  
Vol 2014 ◽  
pp. 1-6 ◽  
Author(s):  
Mizue Matsuura ◽  
Masahiko Inamori ◽  
Hiroki Endo ◽  
Tetsuya Matsuura ◽  
Kenji Kanoshima ◽  
...  
Keyword(s):  
Small Bowel ◽  
Crossover Study ◽  
Capsule Endoscopy ◽  
Healthy Male ◽  
Double Blind ◽  
Placebo Tablet ◽  
Small Bowel Transit Time ◽  
Water Secretion ◽  
Small Bowel Endoscopy

The aim of this study was to investigate the usefulness of lubiprostone for bowel preparation and as a propulsive agent in small bowel endoscopy. Six healthy male volunteers participated in this randomized, 3-way crossover study. The subjects received a 24μg tablet of lubiprostone 60 minutes prior to the capsule ingestion for capsule endoscopy (CE) and a placebo tablet 30 minutes before the capsule ingestion (L-P regimen), a placebo tablet 60 minutes prior to CE and a 24 μg tablet of lubiprostone 30 minutes prior to CE (P-L regimen), or a placebo tablet 60 minutes prior to r CE and a placebo tablet again 30 minutes prior to CE (P-P regimen). The quality of the capsule endoscopic images and the amount of water in the small bowel were assessed on 5-point scale. The median SBTT was 178.5 (117–407) minutes in the P-P regimen, 122.5 (27–282) minutes in the L-P regimen, and 110.5 (11–331) minutes in the P-L regimen (P=0.042). This study showed that the use of lubiprostone significantly decreased the SBTT. We also confirmed that lubiprostone was effective for inducing water secretion into the small bowel during CE.

scholarly journals Lubiprostone improves visualization of small bowel for capsule endoscopy: a double-blind, placebo-controlled 2-way crossover study

2017 ◽  
Vol 05 (06) ◽  
pp. E424-E429
Author(s):  
Mizue Matsuura ◽  
Masahiko Inamori ◽  
Yumi Inou ◽  
Kenji Kanoshima ◽  
Takuma Higurashi ◽  
...  
Keyword(s):  
Small Bowel ◽  
Image Quality ◽  
Crossover Study ◽  
Transit Time ◽  
Capsule Endoscopy ◽  
Secondary Outcome ◽  
Serious Adverse Events ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Significant Difference

Abstract Background and study aims Lubiprostone has been reported to be an anti-constipation drug. The aim of the study was to investigate the usefulness of lubiprostone both for bowel preparation and as a propulsive agent in small bowel endoscopy. Patients and methods This was a double-blind, placebo-controlled, 2-way crossover study of subjects who volunteered to undergo capsule endoscopy (CE). A total of 20 subjects (16 male and 4 female volunteers) were randomly assigned to receive a 24-μg tablet of lubiprostone 120 minutes prior to capsule ingestion for CE (L regimen), or a placebo tablet 120 minutes prior to capsule ingestion for CE (P regimen). Main outcome was gastric transit time (GTT) and small-bowel transit time (SBTT). Secondary outcome was adequacy of small-bowel cleansing and the fluid score in the small bowel. The quality of the capsule endoscopic images and fluid in the small bowel were assessed on 5-point scale. Results The capsule passed into the small bowel in all cases. Median GTT was 57.3 (3 – 221) minutes for the P regimen and 61.3 (10 – 218) minutes for the L regimen (P = 0.836). Median SBTT was 245.0 (164 – 353) minutes for the P regimen and 228.05 (116 – 502) minutes for the L regimen (P = 0.501). The image quality score in the small bowel was 3.05 ± 1.08 for the P regimen and 3.80 ± 0.49 for the L regimen (P < 0.001). The fluid score in the small bowel was 2.04 ± 1.58 for the P regimen and 2.72 ± 1.43 for the L regimen (P < 0.001). There was a significant difference between the 2 regimens with regard to image quality. The fluid score was more plentiful for the L regimen than for the P regimen. There were no cases of capsule retention or serious adverse events in this study. Conclusion Our study showed that use of lubiprostone prior to CE significantly improved visualization of the small bowel during CE as a result of inducing fluid secretion into the small bowel.

Can the Small-Bowel Transit Time Influence the Diagnostic Yields of Capsule Endoscopy?

2006 ◽  
Vol 63 (5) ◽  
pp. AB158
Author(s):  
Young Jig Cho ◽  
Chang Duck Kim ◽  
Bora Keum ◽  
Youn Ho Kim ◽  
Hwi Kong ◽  
...  
Keyword(s):  
Small Bowel ◽  
Transit Time ◽  
Capsule Endoscopy ◽  
Small Bowel Transit ◽  
Small Bowel Transit Time

scholarly journals Performance measures for small-bowel endoscopy: a European Society of Gastrointestinal Endoscopy (ESGE) Quality Improvement Initiative

Endoscopy ◽  
2019 ◽  
Vol 51 (06) ◽  
pp. 574-598 ◽  
Author(s):  
Cristiano Spada ◽  
Deirdre McNamara ◽  
Edward J. Despott ◽  
Samuel Adler ◽  
Brooks D. Cash ◽  
...  
Keyword(s):  
Quality Improvement ◽  
Small Bowel ◽  
Performance Measures ◽  
Capsule Endoscopy ◽  
European Society ◽  
Gastrointestinal Endoscopy ◽  
Quality Improvement Initiative ◽  
Upper Gastrointestinal Endoscopy ◽  
Small Bowel Endoscopy ◽  
First Time

AbstractThe European Society of Gastrointestinal Endoscopy (ESGE) together with the United European Gastroenterology (UEG) recently developed a short list of performance measures for small-bowel endoscopy (i. e. small-bowel capsule endoscopy and device-assisted enteroscopy) with the final goal of providing endoscopy services across Europe with a tool for quality improvement. Six key performance measures for both small-bowel capsule endoscopy and for device-assisted enteroscopy were selected for inclusion, with the intention being that practice at both a service and endoscopist level should be evaluated against them. Other performance measures were considered to be less relevant, based on an assessment of their overall importance, scientific acceptability, and feasibility. Unlike lower and upper gastrointestinal endoscopy, where performance measures had already been identified, this is the first time that small-bowel endoscopy quality measures have been proposed.

Sign in / Sign up

Export Citation Format

Share Document